---
layout: default
title: Umeclidinium
parent: 僅模型預測 (L5)
nav_order: 1030
evidence_level: L5
indication_count: 10
---

# Umeclidinium
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Umeclidinium: From Respiratory Disease to Migraine Disorder

## One-Sentence Summary

Umeclidinium is an inhaled long-acting muscarinic (M3) receptor antagonist (LAMA), a drug class whose action is confined to airway smooth muscle with minimal systemic absorption. The TxGNN model assigns a high score (96.36%) to **Migraine Disorder** as a potential new indication, but **0 clinical trials** and **0 publications** currently support this link — and the model's own generated rationale explicitly states there is no known mechanistic connection between anticholinergic action and migraine pathophysiology.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not on file — based on drug class (inhaled LAMA acting on airway smooth muscle); no official indication text available |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 96.36% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data for umeclidinium is not available in this evidence pack (original MOA field is a data gap). Based on the drug class information present in the prediction rationale, umeclidinium is an inhaled long-acting M3 muscarinic receptor antagonist (LAMA), with its pharmacological action limited to airway smooth muscle and negligible systemic absorption.

For the top-ranked prediction (migraine disorder), the evidence pack's own mechanistic assessment concludes that there is **no known association** between anticholinergic (antimuscarinic) action and migraine pathophysiology (trigeminovascular system, CGRP pathway). This ranking therefore reflects a pure TxGNN network-prediction signal without pharmacological plausibility support.

It is also worth noting that two lower-ranked predictions in this pack (open-angle glaucoma and primary hereditary glaucoma) flag a **known safety risk** rather than a therapeutic opportunity: anticholinergic agents, including inhaled LAMAs, have been reported to precipitate acute angle-closure glaucoma via incidental ocular exposure (e.g., nebulizer mask mist), acting through mydriasis and angle narrowing — mechanistically the *opposite* of a treatment effect. This underscores that TxGNN's raw ranking does not distinguish "risk" signals from "opportunity" signals and requires expert mechanistic review before any indication is advanced.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Singapore Market Information

Umeclidinium is not currently marketed in Singapore. No license registrations are on file (total licenses: 0), so no product-level dosage form or approved-indication data is available for comparison.

---

## Safety Considerations

**Important Signal from Prediction Analysis (not from formal safety data):** Anticholinergic agents in this class, including inhaled LAMAs, carry a reported risk of precipitating acute angle-closure glaucoma via incidental ocular exposure. This should be treated as a contraindication-level caution for any glaucoma-related indication exploration, not as supporting evidence for repurposing.

Beyond this signal, please refer to the package insert for safety information — key warnings, contraindications, and drug interaction data are not currently available (this is flagged as a **Blocking** data gap; see DG001).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (migraine disorder) has a high TxGNN score but zero corroborating clinical trials or literature, and the model's own rationale states there is no plausible pharmacological mechanism linking anticholinergic action to migraine. Combined with the drug's absence from the Singapore market, missing official MOA data, and a **Blocking** gap in TFDA label/safety information, there is insufficient basis to advance this candidate.

**To proceed, the following is needed:**
- TFDA package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirmed mechanism of action from DrugBank or primary label sources (DG002)
- Targeted literature/clinical trial search specific to umeclidinium and migraine (current literature search returned no relevant hits)
- Independent pharmacological review to confirm or refute mechanistic plausibility before any further evaluation stage (S1+)
- If glaucoma-related indications are considered in the future, treat the angle-closure risk signal as a contraindication flag, not a repurposing opportunity
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

